期刊文献+

血清高尔基体蛋白73在慢性肝病患者中的临床应用 被引量:5

Clinical application of serum Golgi protein 73 in patients with chronic liver diseases
原文传递
导出
摘要 高尔基体蛋白73(GP73)是细胞高尔基体上的一种跨膜蛋白,可被切割释放入血。近年来,越来越多的临床研究表明,血清GP73的升高与肝脏疾病密切相关,有望作为评估慢性肝脏疾病进展的新型血清学标志物。现围绕血清GP73对不同病因引起的慢性肝炎、肝纤维化、肝硬化和肝细胞癌中的临床应用进行综述,并对未来研究进行展望。 Golgi protein 73 (GP73) is a transmembrane protein on the Golgi apparatus and can be cut and released into the blood. In recent years, an increasing number of clinical studies have shown that the elevated serum GP73 level is closely related to liver diseases. And thus GP73 is expected to be used as a new serum marker for assessing progress of chronic liver diseases. Herein, the clinical application of serum GP73 in chronic hepatitis, liver fibrosis, liver cirrhosis and hepatocellular carcinoma with different etiologies was reviewed based on available literatures;and a research outlook in this field is made.
作者 刘燕娜 姚明解 郑素军 陈香梅 刘向祎 胡鹏 欧启水 窦晓光 陈红松 段钟平 侯金林 南月敏 高志良 徐小元 庄辉 鲁凤民 Liu Yanna;Yao Mingjie;Zheng Sujun;Chen Xiangmei;Liu Xiangyi;Hu Peng;Ou Qishui;Don Xiaoguang;Chen Hongsong;Duan Zhongping;Hou Jinlin;Nan Yuemin;Gao Zhiliang;Xu Xiaoyuan;Zhuang Hui;Lu Fengmin(Department of Microbiology and Center of Infectious Diseases,Peking University Health Science Center,Beijing 100191,China;Department oj Anatomy and Embtyology School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China;Liver Diseases Center,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China;Department of Clinical Laboratory,Beijing Tongren Hospital,Capital Medical University',Beijing 100730,China;Department of Infectious Diseases,The Second Affiliuted Hospital of Chongqing Medical University,Chongcjing 400010,China;Department of Laboratory Medicine,The First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China;Department of Infectious Diseases,Shengjing Hospital,China Medical University,Shenyang 110022,China;Hepatology,Institute,Peking University People's Hospital,Beijing 100044,China;Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of In fectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Traditional and Western Medical Hepatology,Third Hospital of Hebei Medical University,Shijiazhuang 050051,China;Department of Infectious Diseases,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China;Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China)
出处 《中华肝脏病杂志》 CSCD 北大核心 2022年第1期4-8,共5页 Chinese Journal of Hepatology
关键词 高尔基体蛋白 肝脏疾病 肝脏炎症 肝纤维化 肝硬化 血清标志物 Golgi protein Liver cirrhosis Liver diseases Liver fibrosis Liver inflammation Serum biomarker
  • 相关文献

参考文献10

二级参考文献56

  • 1Mattia Bellan,Luigi Mario Castello,Mario Pirisi.Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review[J].Journal of Clinical and Translational Hepatology,2018,6(3):317-325. 被引量:23
  • 2Nikolaos K.Gatselis,Sarah P.Georgiadou,Nikolaos Tassopoulos,Kalliopi Zachou,Christos Liaskos,Angelos Hatzakis,Georgios N.Dalekos.Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study[J].World Journal of Gastroenterology,2005,11(4):482-487. 被引量:10
  • 3蔺武,刘心娟,魏南,高炳霞,姜国俊,常岩芹.复方鳖甲软肝片抗肝纤维化疗效的系统评价[J].胃肠病学和肝病学杂志,2007,16(1):69-72. 被引量:59
  • 4Triolo M, Corte CD, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014,34 Suppl 1:139-145.
  • 5Calvaruso V, Craxi A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible.'? Liver Int, 2014,34 Suppl 1 : 85 -90.
  • 6Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatoeellular carcinoma in the Asia- Pacific region: consensus statements. J Gastroenterol Hepatol, 2010,25 657-663.
  • 7Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatoeellular carcinoma (HCC) : comments on AASLD guidelines. J Hepatol,2012,57:930-932.
  • 8Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAV1R Cooperative Study Group. Hepatology, 1996,24 : 289-293.
  • 9Wei H, Li B, Zhang R, et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoS One ,2013,8 : e53862.
  • 10Kladney RD,Bulla GA,Guo L,et al.GP73,a novel Golgi-localized protein upregulated by viral infection.Gene,2000,249:53-65.

共引文献174

同被引文献95

引证文献5

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部